Taking advantage of a summer stock climb on the back of its allogeneic cell therapy pipeline, Pluristem Therapeutics Inc. is nearly doubling its cash position with a $32 million public offering. Read More
With one piece of the budget puzzle about to be put in place, at least temporarily, the FDA, National Institutes of Health (NIH) and other federal agencies can start planning for fiscal 2013, which begins in two weeks. Read More
LONDON – Detailed analysis of genes associated with autoimmune diseases has identified three new regions where genetic variation plays a role in determining the risk of the autoimmune liver disease called primary biliary cirrhosis (PBC). Read More
With positive overall survival data from a Phase II trial in hand, 4SC AG aims to move its pan-histone deacetylase inhibitor (HDAC) resminostat into a pivotal Phase III trial in second-line hepatocellular carcinoma (HCC) in the first half of next year. Read More
• Io Therapeutics Inc., of Santa Ana, Calf., presented preclinical data for its compound IRX4204 in animal models of Alzheimer's disease at the 6th Neurodegenerative Conditions Research and Development conference in San Francisco. The results showed attenuation of cognitive deterioration. Read More
• DART Therapeutics LLC, of Cambridge, Mass., named Eugene W. Williams CEO, Ernest D. Bush chief scientific officer, Elliot Goldstein chief medical officer and Cabot Brown chief financial officer. Read More
Scientists at the University of California at San Diego have been able to induce functional recovery after severe spinal cord injury in rats by transplanting the animals with a mix of neural stem cells, fibrin and growth factors. Read More
